Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 24Gastrointestinal 16Genitourinary 13Other 8Head & Neck 7Other hematologic neoplasm 6Thoracic 5Lymphoid 5Plasma cell 4Gynecologic 4CNS 4Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Endocrine 2Other neoplasm 1Myeloid 1Dermatologic 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Resistance Training × Tumor-Agnostic × Clear all
NCT07159815 2026-06-01

REACT

Inland Norway University of Applied Sciences

Phase NA Active not recruiting
160 enrolled
Tumor-Agnostic

Neoplasms

NCT00798200 2016-03-03

CanWell

McMaster University

Phase 1 Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡